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Abstract
Background
As we endeavour to examine rates of viral suppression in PLHIV, reliable data on ART
adherence are needed to distinguish between the respective contributions of poor adher-
ence and treatment failure on high viral load. Self-reported data are susceptible to response
bias and although biomarker data on drug presence and concentration can provide a supe-
rior, alternative method of measurement, complications due to drug-drug interactions and
genetic variations can cause some inaccuracies. We investigate the feasibility of combining
both biomarker and self-report data to produce a potentially more accurate measure of ART
adherence.
Methods
Data were taken from a large general-population survey in the Manicaland province, Zimba-
bwe, conducted in 2009–2011. HIV-infected adults who had initiated ART (N = 560) pro-
vided self-report data on adherence and dried blood spot samples that were analysed for
traces of ART medication. A new three-category measure of ART adherence was con-
structed, based on biomarker data but using self-report data to adjust for cases with abnor-
mally low and high drug concentrations due to possible drug-drug interactions and genetic
factors, and was assessed for plausibility using survey data on socio-demographic
correlates.
Results
94.3% (528/560) and 92.7% (519/560) of the sample reported faithful adherence to their
medication and had traces of ART medication, respectively. The combined measure esti-
mated good evidence of ART adherence at 69% and excellent evidence of adherence at
53%. The regression analysis results showed plausible patterns of ART adherence by
socio-demographic status with men and younger participants being more likely to adhere
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Conclusion
Biomarker and self-reported measures of adherence can be combined in a meaningful way
to produce a potentially more accurate measure of ART adherence. Results indicate that
ART adherence in Manicaland is at best 69%, which not only allows for considerable room
for improvement but also suggests that the area may be falling short of the UNAIDS’ 90%
target regarding viral suppression. Increased efforts are needed to improve ART adherence
particularly amongst the young male population in rural areas of east Zimbabwe.
Introduction
There is concern that people living with HIV (PLHIV) in sub-Saharan African, many of whom
live in poverty and lack formal education, may have suboptimal adherence to HIV antiretrovi-
ral therapy (ART) [1–4]. Consistent adherence to ART is necessary to achieve viral suppres-
sion, prevent drug resistance, reduce transmission and delay disease progression [5,6]. Various
structural and behavioural factors can lead to low adherence [7,8] which in turn can result in
treatment failure. However, treatment failure can occur unrelatedly to adherence as a result of
drug related problems such as drug resistance, poor absorption of medications, inadequate
dosing, and drug-drug interactions. Therefore, reliable data on ART adherence are needed to
distinguish between the respective contributions of poor adherence and treatment failure on
high viral load.
UNAIDS recently set ambitious 90-90-90 targets for the HIV care cascade, with the objec-
tive that, by 2020, 90% of all PLHIV will be diagnosed; 90% of those diagnosed will receive sus-
tained antiretroviral therapy (ART); and 90% of those on ART will have undetectable viral
loads [9]. In order to achieve the last 90% target, it is important to not only identify those who
continue to have detectable viral load despite receiving ART, but also to determine whether
viral suppression has failed as a result of poor adherence, or other drug related problems. It is
crucial to make this distinction as both causes of failed viral suppression require different
solutions.
Self-reports of missed or irregular treatment doses have been used extensively in ART
adherence research. They are inexpensive, easy to implement, and can identify patient-specific
barriers to adherence [10]. However, self-reports are subject to bias with numerous studies
suggesting that participants overstate actual adherence [11,12]. As a result, studies of ART
adherence increasingly incorporate more objective measures into their research, electronic
monitoring (MEMS) being the most common. MEMS caps fit standard-sized medication bot-
tles and record the time and date of each opening as a presumptive dose. Data obtained from
MEMS are often used in conjunction with self-reports to help determine the level of bias
exhibited by the latter [11,13,14]. MEMS caps however are expensive ($80-$100 per cap) and
thus often impractical, particularly in resource-limited settings. Such caps are also unable to
measure whether the patient actually took pills out of the bottle when it was opened, if they
took the correct dose, or if they consumed the pill that was taken out. Furthermore, MEMS
caps are not compatible with patients using pillboxes or otherwise storing medications outside
the capped bottles. Because of their cost, impracticality and inaccuracy, MEMS are particularly
unsuitable for use in large-scale population-based surveys. Such surveys are necessary to obtain
Might ART Adherence Estimates Be Improved by Combining Biomarker and Self-Report Data?
PLOS ONE | DOI:10.1371/journal.pone.0167852 December 14, 2016 2 / 16
academic publications. If further data is required, a
data request form must be completed (available to
download from our website) and submitted to s.
gregson@imperial.ac.uk. If the proposal is
approved, the authors will send a data sharing
agreement which must be agreed upon before we
release the requested data.
Funding: The Manicaland Project is funded by
Wellcome Trust https://wellcome.ac.uk/funding.
Grant Number: 084401/Z/07/B. Recipient is SG.
The funders had no role in study design, data
collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.
representative estimates of population-level adherence as well as risk factors for non-adher-
ence among all PLHIV receiving ART.
A promising but comparatively less widely used objective measure of adherence is use of
biological indicators. Detecting the presence and concentration of anti-retroviral drugs
(ARVs) to determine if all medications are being taken as prescribed has been used successfully
as a biomarker of drug adherence [15] and could be considered as a gold standard measure.
Due to the development and validation of methods which use dried blood spot (DBS) as a sam-
ple matrix, and multiplex LC-MSMS methods that can detect more than one ARV at a time,
this approach could be a useful one in measuring progress towards the third of the UNAIDS’
90-90-90 targets. However, use of ARV biomarkers does have some limitations.
First, it may be necessary to test for a number of different ARVs to establish adherence. The
majority of people living with HIV who are receiving ARVs in SSA do so under a national
ART programme and take the same HAART combination. However, some patients will have
unique combinations after failing the recommended first-line regimens. Whilst, some ART
regimens are given as fixed dose combinations (FDCs) where detection of one component
implies that all components are being taken, in other cases, patients receive separate pills so
that ART detection must be expanded to include multiple components in their various combi-
nations (of which there can be more than four). This can have major cost implications as there
are no methods that can measure all possible combinations simultaneously.
Second, drug exposure can be affected by drug-drug interactions. Sub-therapeutic levels of
NVP can potentially occur, not only from infrequent adherence but also from drug-drug inter-
action, most commonly with Rifampicin-based TB medication. Rifampicin is a potent inducer
of CYP3A4 and an inducer of CYP2C9 [16–18]. NVP is particularly vulnerable to Rifampicin-
based TB treatment [19]. Thai [20] and South African [21] investigators have found sub-thera-
peutic NVP concentrations in 21%-38% of co-infected patients on Rifampicin-based TB treat-
ment taking standard NVP doses. Due to this drug-drug interaction, patients who are taking
TB medication may be found to have sub-therapeutic concentrations of NVP despite adhering
well to ART. In contrast, drugs such as Ketoconazole inhibit enzymes that metabolize some
ARVs [22].
Third, though poor ART adherence can account for toxic concentration levels of (say) NVP
as well as sub-therapeutic concentrations (since patients may take a large dose to compensate
for previous or anticipated future missed doses), the genetic status of patients can also cause
NVP concentrations to deviate from normal. NVP is principally metabolized by CYP3A4 and
CYP2B6 [23,24] although CYP2D6 and CYP2C9 may also play a role [25]. A frequent CYP2B6
variant (516G!T) predicts decreased plasma clearance of NVP and increased plasma NVP
exposure at steady state [26–28]. A less frequent CYP2B6 polymorphism, 983C!T, also pre-
dicts increased plasma NNRTIs exposure of a similar magnitude [29,30]. In short, both
CYP2B6 516G!T and 983T!C are associated with increased steady-state plasma NVP expo-
sure. Investigation of CYP2B6 516G!T polymorphism in various populations has shown that
these alleles are largely absent in Caucasian populations [26,27], yet its frequency is as high as
>34% in African-Americans and Ghanaians [31]. Both Mehlotra [32] and Dhoro [33] have
also found slow metabolism variants of CYP2B6 and CYP3A4 to be particularly prevalent in
west Africa. Patients who possess these alleles are still able to achieve viral suppression assum-
ing they adhere to their ART. Similarly, a genetic variant of the enzyme CYP2B6 slows the
activity of this enzyme, such that patients who possess it retain high levels of Efavirenz (EFZ).
Having consistently high levels of EFZ, in turn, is associated with increased incidence of
adverse drug reactions which can in turn increase the risk for poor adherence.
Fourth, results from tests that detect the presence of ART may be more difficult to interpret
for some ARVs than for others. The presence of short half-life ARVs such as Lamivudine is
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more informative than the presence of long half-life ARVs such as EFZ and Nevirapine. This is
because it is still possible to detect the presence of the latter several days after their intake, mak-
ing poor adherence difficult to estimate. Furthermore, blood concentrations of nucleoside ana-
logue inhibitors such as Lamivudine and Zidovudine do not reflect therapeutic concentrations
since they are prodrugs; by contrast, the concentrations of non-nucleoside analogue inhibitors,
such as EFZ and Nevirapine, do correlate with therapeutic effect. This disconnect between
detection and concentration can complicate data interpretation.
In an attempt to address some of these difficulties in using either self-reports or biomarker
data separately to measure ART adherence, we used data from a general population survey in
east Zimbabwe to:
1. Measure ART adherence based on self-reported data and ARV drug detection;
2. Compare the overall estimates and examine the consistency of results on ART adherence
obtained from these two different methods;
3. Construct a new measure of ART adherence which uses biomarker data in combination
with self-report data where the former may be particularly unreliable; and
4. Assess the plausibility of this new combined measure by examining observed socio-demo-
graphic patterns of adherence.
Data and Methods
Data for this study were taken from the 5th wave of the Manicaland HIV/STD Prevention Proj-
ect [34,35], a longitudinal survey which examines the dynamics of HIV infection and its
impact in eastern Zimbabwe. The Manicaland project data collection team gathered data
between October 2009 and July 2011 in 12 sites representing 4 socio-economic strata: small
towns, agricultural estates, roadside trading centres, and subsistence farming villages (for
more information visit http://www.manicalandhivprojec t.org/data-collection-team.html).
Authors S.Gregson, C. Nyamukapa and A. Takaruza are affiliated with the Manicaland project
and oversaw data collection during this time. In addition to completing a questionnaire, study
participants also provided DBS, these were subject to HIV sero-testing and examined for the
presence and concentrations of anti-retroviral drugs. Written informed consent was obtained
from each study participant. Ethical approval for the Manicaland Project was obtained from
the Medical Research Council of Zimbabwe and the Imperial College Research Ethics
Committee.
DBS provide several advantages over conventional whole blood, plasma or serum sample
collection [36–38]. The method is less invasive as only a small volume is required. DBS are
taken from finger or heel prick as compared to conventional venous cannula. It is cheaper
than collecting whole blood samples, requires simple storage and is easier to transfer as no
freezers or dry ice are required. The dried blood matrix stabilizes many analyses and reduces
the infection risk of HIV/AIDS and other infectious pathogens.
Self-reported ART adherence
All survey participants provided information on their adherence to ART. Reportedly taking
medication regularly regardless of whether they are feeling unwell or not, and not having
stopped or forgotten to take this medication is seen as good evidence of self-reported
adherence.
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Biomarker-based ART adherence
When the data were collected, the most common treatment for HIV was Stelanev (Nevirapine-
NVP, Stavudine-d4T and Lamivudine-3TC)—an FDC. Those who did not tolerate this regi-
men or who were on co-treatment for TB were usually prescribed EFZ in place of NVP or
were given combinations containing other drugs such as Zidovudine (AZT) as non-fixed dose
combinations.
In this study, an LC-MSMS method for the detection of ARVs in DBS samples was devel-
oped according to the method of R ter Heine et al. [39] with minor modifications. DBS were
punched out of a collection paper with a 0.25nm in diameter punch. The analytes were
extracted from the punched-out disc using a mixture of acetonitrile, methanol and 0.2M zinc
sulphate in water (1:1:2, v/v/v) containing the internal standard Ritonavir. Ritonavir was used
as an internal standard as it is highly unlikely that patients would take ritonavir with either
NVP or EFZ. 25 μL (microLitres) of the extract was injected onto the Waters Symmetry
reversed-phase C18 column (50mm x 2.1mm-ID, 5μm) for separation from endogenous com-
pounds. The analytes were quantified using a triple quadrupole mass spectrometer (API3000
Sciex). Due to poor peak resolution in some runs, some samples had ARVs determined either
simultaneously or individually. The analytical run time was 3 mins with AZT, 3TC, NVP, EFZ
and Ritonavir eluting out at 0.700, 0.763, 0.817, 0.615, 0.906 minutes respectively. All ARVs
were analysed in the positive mode except EFZ which was analysed in negative mode in Multi-
ple Reaction Monitoring mode (MRM). The target was to detect at least one ARV in each sam-
ple as a measure of adherence. In some samples, two or three ARVs were determined.
New measure of ART adherence using biomarker data combined with
self-report data
A three-category measure of ART adherence was produced based on drug presence and con-
centration of NVP. Poor adherence was defined as those with only one or no ARVs detected.
Good evidence of adherence was defined as having non-therapeutic levels of NVP and at least
one other ARV detected (non-therapeutic levels of NVP suggest that the participant is either
not taking ART regularly or is taking an increased dose). Excellent adherence was defined as
having therapeutic levels of NVP and at least one other ARV detected. In constructing this
measure, the therapeutic range for NVP concentrations was taken to be 2–10 ug/ml, with con-
centrations below 2ug/ml treated as sub-therapeutic and those above 10ug/ml treated as poten-
tially toxic.
Individuals with extremely high concentrations of NVP may be adhering well but possess
slow metabolism variants of CYP2B6 and CYP3A4. To account for this, we constructed a new
combined measure of ART adherence in which we assumed that those with highly toxic con-
centrations of NVP (>20 ug/ml), at least one other ARV detected, and self-reported good
adherence had therapeutic levels of NVP. In addition, we assumed that participants with sub-
therapeutic levels of NVP who reported taking TB medication and adhering well to ART were
actually adhering to NVP but experiencing a drug-drug interaction.
Social-demographic patterns of adherence
Demographic and socio-economic data from this survey were used to assess the plausibility of
patterns of association between age, gender, socio-economic status, social capital, religion,
marital status and area type and ART adherence in Manicaland using the new combined mea-
sure of adherence. Respondents socio-economic status (SES) was captured using a combined,
four category measure of sellable and non-sellable assets created by Schur et al. [40]. Data on
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religion was categorised according to Manzou’s [41] grouping of Manicaland churches, where
churches were grouped as ‘Christian’, ‘Spiritual’, ‘Traditional’ and ‘Other’. Finally, social capi-
tal was measured in the study as being the number of well-rated community groups that a
respondent belonged to [42].
Bivariate analysis was conducted to test for associations between each of these socio-demo-
graphic variables and the combined measure of ART adherence. Then variables associated
with adherence at p<0.1 were all included in a multivariable, multinomial logistic regression
(poor adherence was used as the reference category).
Results
Self-reported adherence
Analysis was restricted to 607 survey participants who were diagnosed as HIV-positive in the
study and answered ‘yes’ to the question, Have you ever taken any drugs yourself that stop HIV
causing AIDS? 93.3% (n = 566/607) reported adhering to their ART regimen. These partici-
pants were also asked to specify whether they were taking ARVs or Cotrimoxazole. As shown
in Table 1, 101 respondents reported taking Cotrimoxazole, 47 of whom had no trace of ARV
medication in their blood sample. Cotrimoxazole can be taken prior to and/or during ART,
which may have caused some confusion amongst respondents when answering this question.
It is likely that the 54 respondents who reported taking Cotrimoxazole and had ART present
in their blood sample were initiated onto Cotrimoxazole and had transitioned onto ART. The
47 respondents who reported taking Cotrimoxazole and had no trace of ART in their blood
sample had likely yet to begin an ART regimen and, therefore, were excluded from the subse-
quent analysis.
After making this adjustment, 94.3% (n = 528/560) of the sample were reportedly adhering
to their medication—they take this regularly (not just when they feel unwell), have never
stopped for long periods, and do not occasionally forget a dosage.
Biomarker-based ART adherence
No ARVs were detected in 7.3% (n = 41) of the sample. Only NVP was detected in 8.2%
(n = 46), and only either AZT or 3TC (no NVP) was detected in 15.2% (n = 85). NVP and the
presence of 3TC or AZT were detected in 69.3% of the sample (n = 388/560). Overall, results
of DBS analysis showed that 92.7% (519/560) of the sample had at least one ARV present. EFZ
was not found in any of the eligible blood samples; which was as expected since NVP was still
widely prescribed in eastern Zimbabwe during the period of data collection.
Whilst the proportion adhering based on biomarkers was similar to that for self-reported
adherence, we found no relationship between self-reported adherence and presence of ARV
medication. As shown in Table 2, of the 32 participants who self-reported poor adherence,
only 3 (9.4%) had no drugs present. Furthermore, 38 (7.2%) of those who reported good
adherence were found to have no drugs present.
Table 1. Number of participants taking ARV and Co-trimoxazole.
ARV presence in blood sample
What type of drugs are you taking? None > = 1 Total
ARV 39 448 487
Co-trimoxazole 47 54 101
Other 2 17 19
Total 88 519 607
doi:10.1371/journal.pone.0167852.t001
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ART adherence using biomarker data combined with self-report data
Excluding cases where NVP levels were found to be outside the normal therapeutic range but
before accounting for the effects of possible genetic factors and drug-drug interactions, the
combined measure of ART adherence yielded estimates of between 45% (good adherence) and
69% (excellent adherence) (as shown in Table 3). NVP was detected in 77.5% (434/560) of the
DBS samples; of these, 63.1% (274/434) had therapeutic concentrations. The observed distri-
bution of NVP concentrations is shown in Fig 1.
We then created an amended measure of adherence by identifying participants who were
potentially adhering well to their medication, but had non-therapeutic concentrations of NVP
as a result of an interaction with TB medication, or a genetic defect. In our investigation to iden-
tify the latter, we found 47 participants had toxic levels of NVP (>10ug/ml), of whom, 20 had
extremely high concentrations (>20 ug/ml), likely a result of poor drug absorption. 18 of these
20 participants had at least one other ARV detected and self-reported good adherence, suggest-
ing that, aside from having unusually high levels of NVP, they were adhering to their ART. For
our amended measure therefore, these 18 participants were assumed to be experiencing poor
drug absorption as a result of genetic defects and were reclassified from good to excellent ART
adherence. In our investigation to identify potential drug-drug interactions, we found 25 partic-
ipants with sub-therapeutic levels of NVP who reported adhering well and taking TB medica-
tion; these cases were also reclassified from good to excellent ART adherence.
Following these adjustments, the amended measure of adherence (Table 3), combining
data on drug presence and concentration with self-reported data, yielded estimates of adher-
ence between 53% (good adherence) and 69% (excellent adherence).
Socio-demographic patterns of adherence based on the combined
biomarker and self-report measure of adherence
Using the combined measure of adherence that attempts to account for biomarker inaccura-
cies, in a bivariate analysis, we found that better adherence was associated with older ages,
female gender, Christian religion, residence in an agricultural estate or in or close to an urban/
peri-urban area, and higher SES (Table 4). Those who adhered well had a higher proportion of
participants who belonged to the top two SES quintiles than those with poor adherence (Fig 2).
Table 2. Self-reported ART and ARV presence in DBS.
No ARVs present ARVs present Total
Self-reported ART adherence n col% row% n col% row% n col% row%
Bad Adherence 3 7.3 9.4 29 5.6 90.6 32 5.7 100
Good Adherence 38 92.7 7.2 490 94.4 92.8 528 94.3 100
Total 41 100 7.3 519 100 92.7 560 100 100
doi:10.1371/journal.pone.0167852.t002
Table 3. New measure of adherence combining drug presence and NVP concentration while accounting for interaction with TB medication.
Adherence (n = 560) n % Std Er 95% CI
No amendments Poor 172 30.7% 0.02 0.27 0.35
Good 133 23.8% 0.02 0.20 0.27
Excellent 255 45.5% 0.02 0.41 0.50
Amended to account for TB medication and genetic factors Poor 172 30.7% 0.02 0.27 0.35
Good 90 16.1% 0.02 0.13 0.19
Excellent 298 53.2% 0.02 0.49 0.57
doi:10.1371/journal.pone.0167852.t003
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Multinomial regression (Table 5) confirmed that, while accounting for all socio-demo-
graphic factors simultaneously, older participants were more likely have excellent adherence
than younger patients aged 15–29 (30–39 years: OR = 2.18; 95% CI: 0.97–4.88; 40–49 years:
OR = 2.98; 95% CI: 1.30–6.83; 50–65 years: OR = 4.39; 95% CI: 1.67–11.51). Women are also
significantly more likely to have good and excellent levels of adherence than men (good:
OR = 3.47; 95% CI: 1.53–7.86; excellent: OR = 1.85; 95% CI: 1.11–3.10). Those who belonged
to spiritual church denominations (Marange Apostolic, Zviratidzo Apostolic, Other Apostolic,
Zionist and Mughodi church denominations.) were less likely to have excellent adherence
compared to those who attend Christian churches (OR = 0.59; 95% CI: 0.36–0.95). Finally, res-
idents of towns and roadside settlements were more likely to have excellent adherence com-
pared to those in rural villages (towns: OR = 2.12; 95% CI: 1.08–4.13; roadside settlement:
OR = 1.90; 95% CI: 1.05–3.42), and people on ART in tea estates were more likely to have both
good and excellent adherence than those in villages (good: OR = 2.47; 95% CI: 1.09–5.59;
excellent: OR = 3.94; 95% CI: 2.03–7.63).
We replicated the analysis in Table 5 using the un-amended biomarker measure of adher-
ence to compare results obtained from both measures of adherence. In our examination of
these findings we find no significant changes to the patterns of association, likely due to the
relatively small overall sample size and number of re-classifications.
Discussion
The biomarker data obtained for this study were assessed for their ability to provide an accu-
rate alternative to self-reported adherence. Although certainly more accurate than self-
reported adherence, biomarker data indicating drug presence and concentrations within DBS
samples are susceptible to the effects of drug-drug interactions and host genetic defects.
Fig 1. Distribution of concentrations of NVP in participants’ blood samples.
doi:10.1371/journal.pone.0167852.g001
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Table 4. Patterns of association between socio-demographic characteristics and a combined measure of ART adherence (bivariate analysis).
Level of adherence Total
Poor Good Excellent
Covariate No. Row % No. Row % No. Row % No. Row % p†
Age
15–29 20 46.5 8 18.6 15 34.9 43 100 0.037
30–39 71 34.5 35 17 100 48.5 206 100
40–49 55 27.8 28 14.1 115 58.1 198 100
50–65 26 23 19 16.8 68 60.2 113 100
Total 172 30.7 90 16.1 298 53.2 560 100
Gender
Male 45 37.8 10 8.4 64 53.8 119 100 0.018
Female 127 28.8 80 18.1 234 53.1 441 100
Total 172 30.7 90 16.1 298 53.2 560 100
Marital Status
Widowed 56 25.9 37 17.1 123 56.9 216 100 0.335
Divorced/separated 20 30.8 12 18.5 33 50.8 65 100
Still in union 92 34.6 39 14.7 135 50.8 266 100
Total 168 30.7 88 16.1 291 53.2 547 100
Social Capital
No group 44 31.2 23 16.3 74 52.5 141 100 0.980
= >1 group 128 30.5 67 16 224 53.5 419 100
Total 172 30.7 90 16.1 298 53.2 560 100
Member of church group?
Yes 136 29.1 76 16.2 256 54.7 468 100 0.227
No 31 38.3 12 14.8 38 46.9 81 100
Total 167 30.4 88 16 294 53.6 549 100
Employment
Employed 54 29.5 24 13.1 105 57.4 183 100 0.288
Unemployed 118 31.3 66 17.5 193 51.2 377 100
Total 172 30.7 90 16.1 298 53.2 560 100
Education
Primary or less 70 27.2 50 19.5 137 53.3 257 100 0.072
Secondary or higher 102 33.7 40 13.2 161 53.1 303 100
Total 172 30.7 90 16.1 298 53.2 560 100
SES
0 (Low) 22 32.8 21 31.3 24 35.8 67 100 0.003
1 (Middle—low) 66 33.3 26 13.1 106 53.5 198 100
2 (Middle—high) 45 30.4 22 14.9 81 54.7 148 100
3 (High) 39 27.1 21 14.6 84 58.3 144 100
Total 172 30.9 90 16.2 295 53 557 100
Religion
Christian 83 28.6 36 12.4 171 59 290 100 0.014
Traditional/Other 26 31.7 14 17.1 42 51.2 82 100
Spiritual 55 33.7 37 22.7 71 43.6 163 100
Total 164 30.7 87 16.3 284 53.1 535 100
Area Type
Subsistence farming villages 86 39.1 46 20.9 88 40 220 100 <0.001
Roadside settlements 33 30.8 15 14 59 55.1 107 100
(Continued )
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Table 4. (Continued)
Level of adherence Total
Poor Good Excellent
Covariate No. Row % No. Row % No. Row % No. Row % p†
Tea / forestry estates 19 17.6 19 17.6 70 64.8 108 100
Towns 34 27.2 10 8 81 64.8 125 100
Total 172 30.7 90 16.1 298 53.2 560 100
Urbaness (Distance from nearest growth point)
<5 km 40 28.2 19 13.4 83 58.5 142 100 0.052
5–19 km 29 22.3 19 14.6 82 63.1 130 100
20–30 km 53 35.8 26 17.6 69 46.6 148 100
>30 km 48 34.8 26 18.8 64 46.4 138 100
Total 170 30.5 90 16.1 298 53.4 558 100
†chi2 p value for associated between covariate and level of adherence
Variables with p < .1 will be included in multivariable analysis
doi:10.1371/journal.pone.0167852.t004
Fig 2. Mean (and 95%CI) socio-economic status scores by ART adherence group.
doi:10.1371/journal.pone.0167852.g002
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Table 5. Patterns of association between socio-demographic characteristics and a combined measure of ART adherence (multinomial multivari-
ate logistic regression).
ART Adherence (Poor adherence is base) RRR Std. z P 95% Conf.
Excellent Adherence
Age
15–29 - - - - - -
30–39 2.18 0.90 1.89 0.06 0.97 4.88
40–49 2.98 1.26 2.58 0.01 1.30 6.83
50–65 4.39 2.16 3.01 0.00 1.67 11.51
Gender
Male - - - - - -
Female 1.85 0.49 2.36 0.02 1.11 3.10
Religion
Christian - - - - - -
Traditional/Other 0.73 0.22 -1.02 0.31 0.40 1.34
Spiritual 0.59 0.14 -2.17 0.03 0.36 0.95
SES
0 (Low) - - - - - -
1 (Middle—low) 1.07 0.40 0.18 0.86 0.52 2.22
2 (Middle—high) 1.22 0.47 0.51 0.61 0.57 2.61
3 (High) 1.15 0.47 0.35 0.72 0.52 2.56
Education
Primary or less - - - - - -
Secondary or higher 1.10 0.28 0.39 0.70 0.67 1.81
Site Type
Subsistence Farming Villages - - - - - -
Roadside Settlement 1.90 0.57 2.13 0.03 1.05 3.42
Tea / Forestry Estate 3.94 1.33 4.07 0.00 2.03 7.63
Town 2.12 0.72 2.20 0.03 1.08 4.13
Urbanness
<5 km - - - - - -
5–19 km 1.44 0.47 1.12 0.26 0.76 2.74
20–30 km 0.81 0.27 -0.62 0.54 0.42 1.57
>30 km 0.71 0.24 -1.02 0.31 0.37 1.37
Cons 0.27 0.18 -1.92 0.06 0.07 1.03
Good Adherence
Age
15–29 - - - - - -
30–39 1.45 0.75 0.72 0.47 0.53 3.98
40–49 1.18 0.65 0.31 0.76 0.41 3.45
50–65 1.81 1.12 0.96 0.34 0.54 6.09
Gender
Male - - - - - -
Female 3.47 1.45 2.97 0.00 1.53 7.86
Religion
Christian - - - - - -
Traditional/Other 1.33 0.55 0.69 0.49 0.59 3.00
Spiritual 1.63 0.51 1.56 0.12 0.88 3.00
SES
(Continued )
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Upon examination of the data, self-reported adherence was found to be extremely high, as
was the proportion of the sample who had detectable ARVs. However, no relationship was
found between those who had no detectable ARVs and those who reported poor adherence. A
three-category measure of ART adherence was then produced based on ARVs detected and
NVP concentration. This estimated adherence at 45%-69%. We also tentatively proposed a
means of incorporating self-reported data with the biomarker data to avoid misclassifying peo-
ple who adhere to their regimen but are unable to adequately metabolize ARVs. In doing this,
25 people were identified as having potential drug-drug with their TB medications, and 18
were identified as having host genetic defects. Accounting for these issues produced a poten-
tially more accurate measure which estimated adherence at between 53% and 69%, suggesting
that self-reported data, and to a lesser extent biomarker data, may have overestimated adher-
ence. The finding that adherence has been over reported is in line with previous studies which
indicate that self-reported adherence is heavily biased.
Results of bivariate and multinomial multivariate logistic regression analyses showed that
men, younger participants, and participants with lower SES were more likely to adhere poorly
to their ART medication. Results also indicated that church denomination and area type were
significantly related to adherence. Apostolic churches stress faith healing and discourage medi-
cal treatments so it is plausible that members would have poorer adherence. Residents of farm-
ing and rural villages were less likely to adhere well to their ART medication than those in
more urban areas. This could be because those in urban areas, particularly towns, have better
access to health services [43]. Additionally, if residents of tea/forestry estates are too ill to
work, they may be at risk of losing their job, and with it, their home. This may motivate such
residents to adhere well to their ART regimen. These findings are highly plausible, providing
initial support for the validity of our combined measure, although further validation is
required to confirm its utility.
One limitation of this study is that the combined measure of adherence still relies on self-
report data to an extent. However, the most important self-report data used (on taking TB
Table 5. (Continued)
ART Adherence (Poor adherence is base) RRR Std. z P 95% Conf.
0 (Low) - - - - - -
1 (Middle—low) 0.34 0.14 -2.60 0.01 0.15 0.77
2 (Middle—high) 0.46 0.20 -1.75 0.08 0.20 1.10
3 (High) 0.52 0.24 -1.41 0.16 0.21 1.29
Education
Primary or less - - - - - -
Secondary or higher 0.75 0.25 -0.88 0.38 0.39 1.43
Site Type
Subsistence farming villages - - - - - -
Roadside settlements 1.02 0.42 0.06 0.95 0.46 2.27
Tea / forestry estates 2.47 1.03 2.17 0.03 1.09 5.59
Town 0.38 0.20 -1.83 0.07 0.14 1.07
Urbanness
<5 km - - - - - -
5–19 km 1.15 0.53 0.30 0.77 0.47 2.82
20–30 km 0.67 0.31 -0.88 0.38 0.27 1.64
>30 km 0.80 0.36 -0.50 0.62 0.33 1.94
Cons 0.31 0.27 -1.35 0.18 0.06 1.71
doi:10.1371/journal.pone.0167852.t005
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medication) may not suffer from less bias than self-reported ART adherence. We also
acknowledge the lack of certainty regarding the amendments made to our measure of adher-
ence which account for drug interactions and genetic factors (particularly the latter). The
extent to which the sample exhibits genetic abnormalities which interfere with the metabolism
of EFZ and NVP ideally would be confirmed through further genetic testing that we were not
able to conduct in this study.
In a sense, these findings are outdated, as NVP has largely been replaced by EFV in current
regimens, however, these findings are relevant to a wide range of possible treatments. For
example, EFZ can also be affected by similar genetic factors and is also vulnerable to drug-
drug interactions (particularly treatment for hepatitis C), and, as such, could by accounted for
in the same way this study has done with NVP and TB medication.
Finally, we found that, for some participants, there was confusion over whether they were
receiving ART, Cotrimoxazole, or both. Patients in Manicaland may not be given enough
information regarding their ARVs and, as a result, may be unable to make the distinction
between ART and Cotrimoxazole. At the time these data were collected, Cotrimoxazole was
given to those diagnosed but ineligible for ART according to WHO clinical staging. Some
were later given ART in addition to Cotrimoxazole (for opportunistic infections), or transi-
tioned onto ART when they become eligible, possibly with little to no explanation. Particularly
for residents with poor access to further information regarding their regimen, Cotrimoxazole
may have become synonymous with ART treatment in Manicaland. Therefore, it is important
that health personnel fully inform their patients about their medication and specifically why
they are being put onto Cotrimoxazole and/or ART after testing positive. This may help to
reduce patient confusion and improve future efforts to measure ART adherence.
We acknowledge that of the 18 people who were reclassified under the assumption that
their high levels of NVP were a result of genetic defect, some may simply have been taking too
much of their medication. However, given the unusually high levels of NVP, and the preva-
lence of genetic factors amongst the population we propose that those with highly toxic con-
centrations of NVP (>20 ug/ml), at least one other ARV detected, and self-reported good
adherence are potentially adhering well but are unable to properly metabolise NVP. This can
potentially be confirmed with the use of MEMS in future studies. In the introduction of this
paper, MEMS was deemed to be an unsuitable method of measuring adherence in large-scale
general population surveys, mostly for reasons of cost. However, MEMS could be used to mea-
sure adherence in smaller subgroups identified using our proposed combined measure of
adherence. Measuring adherence levels in this subgroup with MEMS could help to determine
the likelihood of genetic factors interfering with drug metabolism.
Overall, this research demonstrates that biomarker and self-reported measures of adher-
ence can be combined in a meaningful way to produce a potentially more accurate measure of
ART adherence. Results of this analysis indicate that Manicaland, in the period the study was
conducted, good evidence of adherence estimated at between 54% and 69%. Increased efforts
are needed to improve ART adherence particularly amongst the young male population in
rural areas of east Zimbabwe, if the area is to meet these UNAIDS’ targets by 2020.
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